Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or ampli...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei, Chiara, Dizman, Nazli, Schepisi, Giuseppe, Cursano, Maria Concetta, Basso, Umberto, Santini, Daniele, Pal, Sumanta K., De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878604/
https://www.ncbi.nlm.nih.gov/pubmed/31803255
http://dx.doi.org/10.1177/1758835919890285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878604/
https://www.ncbi.nlm.nih.gov/pubmed/31803255
http://dx.doi.org/10.1177/1758835919890285

Ejemplares similares